Valuation: Protalix BioTherapeutics, Inc.

Market Cap 220M 197M 183M 167M 314M 21.28B 316M 2.2B 861M 10.82B 826M 808M 34.79B P/E 2026 *
11.4x
P/E 2027 * 54.6x
Enterprise Value 220M 197M 183M 167M 314M 21.28B 316M 2.2B 861M 10.82B 826M 808M 34.79B EV / Sales 2026 *
2.68x
EV / Sales 2027 * 3.31x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.37%
1 week-1.45%
Current month-1.45%
1 month+2.64%
3 months+15.25%
6 months+24.20%
Current year+51.11%
1 week 2.6
Extreme 2.6
2.77
1 month 2.6
Extreme 2.595
2.85
Current year 1.72
Extreme 1.72
3.19
1 year 1.6
Extreme 1.6
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 29/06/2019
Director of Finance/CFO 57 23/08/2025
Chief Tech/Sci/R&D Officer - 31/05/2024
Director TitleAgeSince
Director/Board Member 73 30/06/2008
Director/Board Member 83 31/10/2014
Director/Board Member 59 29/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Director

25,500 0.0316%
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

480,000 0.5957%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-1.45%+8.80%+77.78% 220M
+2.70%+2.72%+40.88%+107.87% 1,032B
+1.49%-2.22%+37.04%+63.27% 614B
+1.82%+3.77%+16.59%+82.06% 471B
+0.61%-1.80%+62.86%+36.54% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.40%-2.01%+39.76%+52.12% 218B
+1.79%-1.43%+25.81%+95.74% 179B
Average +1.57%-2.98%+26.53%+60.85% 371.51B
Weighted average by Cap. +1.93%-3.18%+31.99%+69.42%

Financials

2026 *2027 *
Net sales 82.16M 73.41M 68.49M 62.21M 117M 7.95B 118M 823M 322M 4.04B 308M 302M 12.99B 66.48M 59.4M 55.42M 50.34M 94.8M 6.43B 95.51M 666M 260M 3.27B 250M 244M 10.51B
Net income 19.63M 17.54M 16.37M 14.86M 28M 1.9B 28.21M 197M 76.83M 966M 73.7M 72.11M 3.1B 3.79M 3.39M 3.16M 2.87M 5.41M 367M 5.45M 38.01M 14.85M 187M 14.24M 13.94M 600M
Net Debt - -
Projected Income Statement - Annual - Protalix BioTherapeutics, Inc.
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
07/10/26 US$2.700 -1.10% 643,064
06/10/26 US$2.730 +0.74% 934,737
05/10/26 US$2.710 0.00% 984,060
02/10/26 US$2.710 +1.12% 947,405
01/10/26 US$2.680 -2.90% 1,589,280
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Protalix BioTherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.730USD
Average target price
11.00USD
Spread / Average Target
+302.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Protalix BioTherapeutics, Inc.